FDA to hold a joint committee meeting

The Psychopharmacologic Drugs Advisory Committee and the Peripheral & Central Nervous System Drugs Advisory Committee will discuss Otsuka Pharmaceutical and Lundbeck’s supplemental New Drug Application (sNDA) 205422-s009, efficacy supplement for REXULTI (brexpiprazole) tablets, for proposed treatment of agitation associated with Alzheimer’s dementia at a meeting being held virtually on April 14 at 9 am. Webcast Link